Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.
Negri
T
T
Casieri
P
P
Miselli
F
F
Orsenigo
M
M
Piacenza
C
C
Stacchiotti
S
S
Bidoli
P
P
Casali
P G
PG
Pierotti
M A
MA
Tamborini
E
E
Pilotti
S
S
D001549:Benzamides; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D017024:Chemotherapy, Adjuvant; D002817:Chordoma / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D018450:Disease Progression; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence / Q000379:methods; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000378:metabolism; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D019009:Proto-Oncogene Proteins c-kit / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D012680:Sensitivity and Specificity
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit; D020796:Receptor, Platelet-Derived Growth Factor alpha; D020797:Receptor, Platelet-Derived Growth Factor beta